Howell, who joined the company as chief commercial officer in October 2023, succeeds Brent Vaughan. Vaughan has led Cognito as CEO since taking the corner office in 2020.
Cambridge, Massachusetts–based Cognito develops the Spectris neuromodulation system. Spectris could provide disease-modifying therapy for treating Alzheimer’s disease. The non-invasive neuromodulation device delivers proprietary gamma frequency light and sound stimulation to treat central nervous system (CNS) diseases.
The company presented positive data for Spectris earlier this year and featured on our list of 7 neurotech companies you need to know.
Cognito said in a news release that Howell’s appointment comes as the company nears enrollment completion in its HOPE pivotal study. The company believes his commercialization expertise suits the role as the company focuses on its next steps with Spectris.
Gerald Chan, Cognito’s board chair, said Howell brings a “proven track record in medical device launches.” He has more than 20 years of expertise in medical devices, Cognito said. He previously served as SVP and GM of Aetion’s Medical Device and Diagnostic group. Before that, he had a nearly 15-year stint at Medtronic. There, he led the company’s value-based healthcare partnerships organization and P&L responsibility for the company’s integrated health solutions program.
“I am honored to take on the role of CEO at Cognito, a company that is at the forefront of innovation in the treatment of neurodegenerative diseases,” said Howell. “Our mission is to improve the lives of patients and families affected by neurodegenerative diseases. I am committed to leading with a focus on the needs and well-being of those we serve, ensuring that every decision we make is aligned with our core values of serving patients.”
